Ryan M. Confer
AeroLeads people directory · profile

Ryan M. Confer Email & Phone Number

President & CEO @ Genprex | Oncology & Diabetes Gene Therapies at Genprex, Inc.
Location: Austin, Texas, United States 10 work roles 3 schools
2 work emails found @genprex.com 6 phones found area 512 and 732 LinkedIn matched
✓ Verified Jul 2026 4 data sources Profile completeness 100%

Contact Signals · 2 work emails · 6 phones

Work email r****@genprex.com
Direct phone (512) ***-****
LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Role
President & CEO @ Genprex | Oncology & Diabetes Gene Therapies
Location
Austin, Texas, United States

Who is Ryan M. Confer? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Ryan M. Confer is listed as President & CEO @ Genprex | Oncology & Diabetes Gene Therapies at Genprex, Inc., based in Austin, Texas, United States. AeroLeads shows a work email signal at genprex.com, phone signal with area code 512, 732, and a matched LinkedIn profile for Ryan M. Confer.

Ryan M. Confer previously worked as President, Chief Executive Officer, & Director at Genprex, Inc. and Chief Financial Officer at Genprex, Inc.. Ryan M. Confer holds Master Of Science In Technology Commercialization, Entrepreneurship from Texas Mccombs School Of Business.

Company email context

Email format at Genprex, Inc.

This section adds company-level context without repeating Ryan M. Confer's masked contact details.

{first_initial}{last}@genprex.com
89% confidence

AeroLeads found 2 current-domain work email signals for Ryan M. Confer. Compare company email patterns before reaching out.

Profile bio

About Ryan M. Confer

An entire career focused on identifying and investing in emerging and disruptive technologies in academic and lab settings and licensing, investing, building, and translating these technologies to commercial application.At Genprex, our team is dedicated to advancing REQORSA, a tumor fighting DNA gene therapy utilizing a first-of-its-kind, non-viral, systemic delivery platform in cancer that we refer to as ONCOPREX. We achieved safety and efficacy in 5 different clinical trials and have 3 FDA fast-track designations (FTDs) and an orphan drug designation exploring RESORSA in advanced stage lung cancer. Our teams have also pioneered a state-of-the-art diabetes therapy utilizing an autologous-based gene therapy via an endoscopic procedure. This approach has the potential to disrupt the traditional insulin market buy allowing existing cells to go through processes of transdifferentiation and dedifferentiation to treat both Type 1 and Type 2 diabetes organically with limited, if any, need for insulin therapy.Outside of Genprex, I support other technology-driven projects which I maintain a strategic or passion-driven purpose and have personally invested including SaaS, medical devices, fintech, industrial design, and motorsport.

Listed skills include Start Ups, Entrepreneurship, Strategy, Business Planning, and 48 others.

Current workplace

Ryan M. Confer's current company

Company context helps verify the profile and gives searchers a useful next step.

Genprex, Inc.
Genprex, Inc.
President & CEO @ Genprex | Oncology & Diabetes Gene Therapies
AeroLeads page
10 roles

Ryan M. Confer work experience

A career timeline built from the work history available for this profile.

President, Chief Executive Officer, & Director

Current

Austin, Texas, Us

Genprex (NASDAQ::GNPX) is a clinical-stage biopharmaceutical company focused on the development of novel gene therapies for patients with cancer and diabetes who have limited treatment options. The Company works with world-class research institutions to identify and advance emerging and disruptive therapies.Genprex’s oncology program utilizes a unique, proprietary, non-viral nanoparticle delivery system, called "Oncoprex", to deliver cancer fighting genes back into the human body. Oncoprex is first systemic gene therapy delivery platform used for cancer in humans. Genprex's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for lung cancer (NSCLC and SCLC). The FDA has granted three Fast Track Designations and an Orphan Drug Designation for REQORSA for lung cancer patients in combination with approved therapies from AstraZeneca, Merck and Genentech. Genprex’s diabetes program utilizes a novel infusion process to deliver genes locally to the pancreas through a traditional ERCP via AAV delivery to convert alpha cells into beta-like cells via transdifferentiation. These beta-like cells are able to produce insulin and are distinct enough from beta cells to evade the typical immune response associated with T1D. Our preclinical programs have shown statistically significant results in the creation of new beta cell mass and insulin production and sustained glucose stabilization over durable periods in humanized mice, human islet cells, and non-human primates subjects. For more information, please visit www.genprex.com.

May 2024 - Present

Chief Financial Officer

Austin, Texas, Us

Sep 2016 - May 2024

Chief Operating & Financial Officer

Austin, Texas, Us

Dec 2013 - Sep 2016

Operations & Finance Manager

Austin, Texas, Us

Jun 2011 - Dec 2013

Strategic Advisor

Austin, Texas, Us

I worked closely with founding CEO, David Nance (former CEO of Introgen Therapeutics), to build a strategic business and financial plan to launch the company and seek early-stage investment.

Apr 2009 - Jun 2011

Co-Founder, Vice President, & Director

Current

Austin, Texas, Us

Gurnade is a creative design agency and automotive tuner. The Company's bread-and-butter is the development of hyper-realistic conceptual designs and their subsequent conversion into high-quality products (what industry refers to as "render to reality"). Our quality craftsmanship has lead to collaboration and partnerships with some of the most reputable automotive brands in the world. Gurnade's work has been on display at the largest and most renown automotive shows in the world (e.g. the SEMA Show, the LA Auto Show, Tokyo Auto Salon, etc).

Jan 2009 - Present

Principal

Current

Confer Capital, Inc is a technology-focused advisory services boutique with a focus on transitioning ideas thru commercialization. We have specialized client advisors that have broad and focused advisory in industries including biopharma, medical devices, SaaS, oil & gas, and financial services. Our core competencies include: negotiating technology licensing and transfer, developing strategic financial and business model analysis, market analysis and GTM strategy, investment analysis and strategy, private and public market financing, investor relations, sales and product development strategies, and advanced growth strategies.

Jun 2008 - Present

Co-Founder, Chief Operating & Financial Officer

Innovate Texas Foundation connects Texas's wealth of intellectual capital with financial capital, human capital, entrepreneurs, universities, businesses, government, and technology communities to strengthen Texas as a global leader in the innovation economy and to create economic abundance for Texans.• Mission & strategy endorsed in July 2008 State of Texas' Competitiveness Councils (nominated by Gov Rick Perry) Report;• Spearheaded research of >3000 Texas stakeholders determining lack of access to innovation resources;• Raised over $2M funding from Department of Labor grants & private donors to launch organization;• Mentored & advised over 250 technology commercialization projects & start-up companies;• Completed over 20 professional and executive training seminars on the topics of technology transfer, development, and commercialization to approximately 1000 attendees from 2009 to 2011;• Collaborated with major Texas universities (UT, TAMU, TTU, TXST) to develop technology commercialization curriculum;• Responsible for annual financial reporting, financial analysis and modeling, finance, accounting, compliance, human resources, operations, marketing, and technology development for the entity;• Managed several independent teams of 5-10 domain experts on the development of internal technical programs and evaluation of outside/spin-off technology transfer and commercialization opportunities;• Evaluated market opportunities, developed strategic business plans, assembled technical and business development teams, and developed strategic and financial partnerships to launch entities/initiatives;• Identified roles, interviewed, and hired management and technical employees, independent contractors, technical specialists, and specialized professional services firms; and• Identified commercially viable military technologies, recruited technical team members, negotiated SRAs, and filed for DOD and DARPA grants to enhance technology readiness level and valuation.

May 2008 - Dec 2012

Senior Investment Manager

Texas Emerging Technology Fund

• Active Manager of a portfolio of 120+ early-stage start-up companies for a $500M+ early-stage technology investment fund;• Researched emerging technologies, markets, and industries to support due diligence and investment screening;• Managed relationships and trained eight regional commercialization deal-flow centers (RCICs) on investment screening best practices;• Negotiated deals and determined value-driven contractual milestones to trigger funding tranches; • Maintained cap tables, developed financial models, and developed portfolio management processes and metrics to monitor investment risk and evaluate deal and fund performance; and• Recognized nationally as the "Most Active Early-Stage Technology Venture Fund in the United States." - June 2008

Sep 2006 - Feb 2009

Financial Analyst

Texas Economic Development Bank

• Performed financial analysis on over $2B in proposals to the Industrial Revenue Bond Program (IRB);• Developed liquidity & default risk provisions and a tiered lending structure for the Texas Leverage Fund (TLF);• Developed and proposed a revised operations and investment strategy for the Product Development & Small Business Incubator Programs (PDSBI);• Performed analysis and developed financial models for over $50M in proposals to the Texas Enterprise Fund (TEF); and• Trained finance team members on the development and usage of financial models to conduct analysis.

Sep 2006 - Aug 2007
3 education records

Ryan M. Confer education

Master Of Science In Technology Commercialization, Entrepreneurship

Texas Mccombs School Of Business

Bsba, Finance & Legal Studies

Bloomsburg University Of Pennsylvania

Finance And Economics

Penn State University
FAQ

Frequently asked questions about Ryan M. Confer

Quick answers generated from the profile data available on this page.

What company does Ryan M. Confer work for?

Ryan M. Confer works for Genprex, Inc..

What is Ryan M. Confer's role at Genprex, Inc.?

Ryan M. Confer is listed as President & CEO @ Genprex | Oncology & Diabetes Gene Therapies at Genprex, Inc..

What is Ryan M. Confer's email address?

AeroLeads has found 2 work email signals at @genprex.com for Ryan M. Confer at Genprex, Inc..

What is Ryan M. Confer's phone number?

AeroLeads has found 6 phone signal(s) with area code 512, 732 for Ryan M. Confer at Genprex, Inc..

Where is Ryan M. Confer based?

Ryan M. Confer is based in Austin, Texas, United States while working with Genprex, Inc..

What companies has Ryan M. Confer worked for?

Ryan M. Confer has worked for Genprex, Inc., Gurnade, Inc., Confer Capital, Inc., Innovate Texas Foundation, and Texas Emerging Technology Fund.

How can I contact Ryan M. Confer?

You can use AeroLeads to view verified contact signals for Ryan M. Confer at Genprex, Inc., including work email, phone, and LinkedIn data when available.

What schools did Ryan M. Confer attend?

Ryan M. Confer holds Master Of Science In Technology Commercialization, Entrepreneurship from Texas Mccombs School Of Business.

What skills is Ryan M. Confer known for?

Ryan M. Confer is listed with skills including Start Ups, Entrepreneurship, Strategy, Business Planning, Venture Capital, Strategic Planning, Business Strategy, and Due Diligence.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.